Tango Therapeutics reports $337M cash, $42M ATM proceeds, runway into late-2026

Tango Therapeutics, Inc.

Cash, cash equivalents and marketable securities at Dec 31, 2023: $337M (unaudited).
Net proceeds of $42M from at-the-market offering completed in January 2024.
Company estimates sufficient cash to fund operations into late-2026.
Figures are preliminary and subject to completion of financial closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.